

PRESS RELEASE

Noida, Tuesday, October 28, 2014

JUBILANT LIFE SCIENCES

The Board of Jubilant Life Sciences Limited, an integrated pharmaceutical and life sciences company met today to approve financial results for the quarter ended September 30, 2014.

Commenting on the Company's performance, Mr. Shyam S Bhartia, Chairman & Managing Director and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Life Sciences said:

“The company's performance in the quarter was affected mainly due to the continued impact of USFDA Warning letter on Spokane facility and adverse price impact on account of new capacities and regulatory changes in China in Advanced Intermediates business. Our Radiopharmaceuticals business has started to show the benefits of our strategic initiatives.”

Q2 FY15 Highlights

- Consolidated revenue at Rs. 1,371 Crore
 - Pharmaceuticals revenue at Rs. 614 Crore
 - LSI revenue at Rs. 757 Crore, up 2% YoY
- International revenues at Rs. 955 Crore, contributing 70% to the overall mix
- EBITDA at Rs. 137 Crore and margins at 10%

H1 FY15 Highlights

- Consolidated revenue at Rs. 2,844 Crore, up 2% YoY
 - Pharmaceuticals revenue at Rs. 1,218 Crore
 - LSI revenue at Rs. 1,626 Crore, up 12% YoY
- International revenues at Rs. 2,006 Crore, contributing 71% to the overall revenues
- EBITDA at Rs. 287 Crore and margins at 10.1%

Pharmaceuticals Segment Review

In Q2 FY2015, Income from Operations of the Pharmaceuticals segment stood at Rs 614 Crore, contributing 45% to the revenue mix. The segment EBITDA stood at Rs. 69 Crore, with EBITDA margins at 11.3%. Excluding one-time expenses of Rs. 35 Crore, the margins for the segment stood at 17%.

For H1 FY2015, Income from Operations stood at Rs. 1,218 Crore, contributing 43% to the overall revenue mix. The segment EBITDA stood at Rs 105 crore, with EBITDA margins at 8.6%. Excluding one-time expenses of Rs. 45 Crore, the margins for the segment stood at 12.3%.



Life Science Ingredients Segment Review

In Q2 FY2015, Income from Operations from the Life Science Ingredients segment was at Rs. 757 Crore, up 2% YoY and contributing 55% to the revenue mix. The segment EBITDA stood at Rs 62 Crore, with EBITDA margins at 8.2%.

In H1 FY2015, Income from Operations of the segment was at Rs 1,626 crore, up 12% YoY and contributing 57% to the revenue mix. The segment EBITDA stood at Rs 195 crore, with EBITDA margins at 12%.

Geographical Overview

In Q2 FY2015, revenues from North America stood at Rs. 513 crore, contributing 37% to the overall revenues. Revenues from Europe and Japan stood at Rs. 277 crore, contributing 20% to the revenue mix. Domestic revenues grew 14% YoY at Rs. 416 crore and thus contributing 30% to the mix. Revenues in ROW including China stood at Rs. 165 crore, thus contributing 12% contribution to the mix.

In H1 FY2015, revenues from North America stood at Rs. 1,003 crore, contributing 35% to the revenue mix. Revenues from Europe and Japan stood at Rs. 607 crore, contributing 21% to the revenue mix and growing 5% YoY. Revenues from ROW including China stood at Rs. 396 crore, contributing 14% to the revenue mix. Domestic revenues stood at Rs. 839 crore, up 17% YoY and contributing 29% to the revenue mix.

Outlook

We expect to deliver stable performance in our business from Q4 FY2015 with operations becoming normal in our CMO business, expected new launches in Solid Dosage Formulations business and better performance in Radiopharmaceuticals.



About Jubilant Life Sciences

Jubilant Life Sciences Limited is a global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients. It also provides services in Contract Manufacturing of Sterile Injectables and Drug Discovery and Development. The Company's strength lies in its unique offerings of Pharmaceutical and Life Sciences products and services across the value chain. With 10 world-class manufacturing facilities in India, US and Canada and a team of around 6200 multicultural people across the globe, the Company is committed to deliver value to its customers spread across over 100 countries. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals and life sciences companies globally. For more info: www.jubl.com

For more information please contact:

For Investors

Ravi Agrawal
Jubilant Life Sciences Limited
Ph: +91-120 436 1002
E-mail: ravi_agrawal@jubl.com

Siddharth Rangnekar
CDR India
Ph: +91 22 6645 1209
E-mail: siddharth@cdr-india.com

Anupam Jain
Jubilant Life Sciences Limited
Ph: +91-120 436 1021
E-mail: anupam_jain@jubl.com

Karl Kolah
CDR India
Ph: +91 22 6645 1220
E-mail: karl@cdr-india.com

For Media

Neha Garg
Jubilant Life Sciences Limited
Ph: +91-120 436 1067
E-mail: neha_garg@jubl.com

Aditi Johari
Perfect Relations
Ph: +91 9953529350
E-mail: ajohari@perfectrelations.com

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.